Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
Clinical Focus
News
Conferences
Media
Publications
Resources
Subscribe
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Breast Cancer
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR+ Lung Cancer
  • Follicular Lymphoma
  • GI Cancers
  • HCC
  • HER2-Positive Breast Cancer
  • Lung Cancer
  • Lymphomas
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLC

May 9, 2019
Tony Mok, MD
Tony Mok, MD

Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.

Tony Mok, MD, a professor in the department of clinical oncology at the Chinese University of Hong Kong, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non—small cell lung cancer (NSCLC) after the phase III KEYNOTE-042 trial.

The current standard indication has been well-defined by a number of available studies as either monotherapy or in combination, says Mok. One of the next steps includes answering the question of how resistance to single-agent pembrolizumab can be managed.

The next step includes identifying how pembrolizumab can be used as a frame for other immunotherapy agents. Mok says it is still very risky business as there are several negative data that have come out already, but if there is an advantage, it needs to be used.